MedPath

SANARIA INC.

SANARIA INC. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

27

Active:1
Completed:23

Trial Phases

2 Phases

Phase 1:23
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials

Phase 1
23 (85.2%)
Phase 2
4 (14.8%)

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Phase 1
Not yet recruiting
Conditions
Malaria Falciparum
Interventions
Biological: PfSPZ-LARC2 Vaccine
Other: Normal Saline (Placebo)
Biological: PfSPZ Challenge (NF54)
First Posted Date
2025-03-06
Last Posted Date
2025-03-06
Lead Sponsor
Sanaria Inc.
Target Recruit Count
58
Registration Number
NCT06862453
Locations
🇩🇪

University of Tubingen, Wilhelmstraße 27, Tubingen, Germany

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

Phase 1
Recruiting
Conditions
Malaria Falciparum
Malaria Infection
Interventions
Biological: PfSPZ-LARC2 Vaccine
Biological: Normal Saline (Placebo)
First Posted Date
2024-10-22
Last Posted Date
2025-04-09
Lead Sponsor
Sanaria Inc.
Target Recruit Count
75
Registration Number
NCT06652737
Locations
🇧🇫

Groupe de Recherche Action en Santé (GRAS) / Unité de Recherche Clinique de Sabou, Ouagadougou, Burkina Faso

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

Phase 1
Terminated
Conditions
Malaria,Falciparum
Malaria
Interventions
Biological: PfSPZ Challenge (7G8)
Other: Normal Saline
First Posted Date
2022-11-03
Last Posted Date
2024-11-25
Lead Sponsor
Sanaria Inc.
Target Recruit Count
31
Registration Number
NCT05604521
Locations
🇺🇸

University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

Phase 1
Completed
Conditions
Malaria
First Posted Date
2021-07-19
Last Posted Date
2022-07-18
Lead Sponsor
Sanaria Inc.
Target Recruit Count
54
Registration Number
NCT04966871
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

PfSPZ Vaccine Trial in Malian Children

Phase 2
Completed
Conditions
Malaria,Falciparum
Malaria
First Posted Date
2021-06-25
Last Posted Date
2024-02-07
Lead Sponsor
Sanaria Inc.
Target Recruit Count
290
Registration Number
NCT04940130
Locations
🇲🇱

Malaria Research and Training Center, Bamako, Mali

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

Experimental Malaria Vaccine Shows Lasting Protection in Clinical Trials

An experimental malaria vaccine, PfSPZ Vaccine, demonstrated significant protection against parasite infection and clinical malaria for up to two years in healthy Malian adults.

© Copyright 2025. All Rights Reserved by MedPath